Longevity & AgingTargeted Cell Fusion Boosts Monoclonal Antibody Production Sixfold
French researchers at CEA/INRAE have significantly upgraded 50-year-old hybridoma technology by pre-selecting antibody-secreting cells (ASCs) before cell fusion. Using a five-marker flow cytometry panel (CD3, TACI, CD138, MHC-II, B220), they identified a distinct plasmablast subset that secretes high levels of antigen-specific antibodies. Fusing these sorted TACI-high/CD138-high cells via electrofusion yielded viable hybridomas in 100% of culture wells versus only 40% with unsorted cells. Over 60% of resulting hybridomas produced antigen-specific monoclonal antibodies, including high-affinity IgGs below 10⁻⁹ M. This targeted approach dramatically improves efficiency without requiring exotic instrumentation, potentially broadening access to high-quality monoclonal antibodies for diagnostics, therapeutics, and research.
